VKTX:NSC-Viking Therapeutics Inc. (USD)

EQUITY | Biotechnology | NASDAQ Capital Market

Last Closing

USD 62.75

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Volume

2.12M

Analyst Target

USD 18.64
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Viking Therapeutics Inc is a clinical-stage biopharmaceutical company. The Company develops therapies for metabolic and endocrine disorders. It includes portfolio of five drug candidates in clinical trials or preclinical studies.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-05-26 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

N/A

USD 124.65B
REGN Regeneron Pharmaceuticals Inc

N/A

USD 110.51B
MRNA Moderna Inc

N/A

USD 57.87B
BNTX BioNTech SE

N/A

USD 24.18B
ARGX argenx NV ADR

N/A

USD 23.04B
ALNY Alnylam Pharmaceuticals Inc

N/A

USD 20.29B
GMAB Genmab AS

N/A

USD 18.17B
BGNE BeiGene Ltd

N/A

USD 17.74B
RPRX Royalty Pharma Plc

N/A

USD 16.18B
BMRN Biomarin Pharmaceutical Inc

N/A

USD 15.32B

ETFs Containing VKTX

XSGI:LSE Xtrackers S&P Global Infr.. 4.59 % 0.00 %

N/A

USD 0.22B
DX2E:F Xtrackers - S&P Global In.. 4.59 % 0.00 %

N/A

USD 0.21B
DX2E:XETRA Xtrackers - S&P Global In.. 4.59 % 0.00 %

N/A

USD 0.21B
XSGI:SW Xtrackers S&P Global Infr.. 4.59 % 0.00 %

N/A

USD 0.22B
CURE:AU ETFS S&P Biotech ETF 1.18 % 0.00 %

N/A

USD 0.04B
VRTGX Vanguard Russell 2000 Gro.. 0.65 % 0.00 %

N/A

USD 1.19B
VTWG Vanguard Russell 2000 Gro.. 0.65 % 0.20 %

N/A

USD 0.91B
R2SC:LSE SPDR® Russell 2000 US Sm.. 0.33 % 0.00 %

N/A

USD 2.76B
R2US:LSE SPDR® Russell 2000 US Sm.. 0.33 % 0.00 %

N/A

USD 2.76B
R2US:PA SSgA SPDR ETFs Europe II .. 0.33 % 0.00 %

N/A

USD 2.76B
ZPRR:F SSgA SPDR ETFs Europe II .. 0.33 % 0.00 %

N/A

USD 2.91B
ZPRR:XETRA SPDR® Russell 2000 US Sm.. 0.33 % 0.00 %

N/A

USD 2.91B
R2US:SW SPDR® Russell 2000 US Sm.. 0.33 % 0.00 %

N/A

USD 2.76B
XRSG:LSE Xtrackers Russell 2000 UC.. 0.33 % 0.00 %

N/A

USD 1.00B
XRSU:LSE Xtrackers Russell 2000 UC.. 0.33 % 0.00 %

N/A

USD 1.00B
XRS2:F Xtrackers (IE) Public Lim.. 0.33 % 0.00 %

N/A

USD 1.19B
XRS2:XETRA Xtrackers Russell 2000 UC.. 0.33 % 0.00 %

N/A

USD 1.19B
XRS2:SW Xtrackers Russell 2000 UC.. 0.33 % 0.00 %

N/A

USD 1.00B
VRTIX Vanguard Russell 2000 Ind.. 0.32 % 0.00 %

N/A

USD 10.02B
VTWO Vanguard Russell 2000 Ind.. 0.32 % 0.15 %

N/A

USD 9.06B
BBC Virtus LifeSci Biotech Cl.. 0.00 % 0.79 %

N/A

USD 0.01B
FSMD Fidelity Small-Mid Factor 0.00 % 0.00 %

N/A

USD 0.33B
SBIO ALPS Medical Breakthrough.. 0.00 % 0.50 %

N/A

USD 0.10B
XGID:LSE Xtrackers S&P Global Infr.. 0.00 % 0.00 %

N/A

USD 0.21B
BBSC JPMorgan BetaBuilders U.S.. 0.00 % 0.00 %

N/A

USD 0.48B
ULTY Tidal Trust II 0.00 % 0.00 %

N/A

USD 0.04B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 237.18% 98% N/A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 237.18% 98% N/A 99% N/A
Trailing 12 Months  
Capital Gain 194.46% 97% N/A 98% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 194.46% 97% N/A 98% N/A
Trailing 5 Years  
Capital Gain 700.38% 97% N/A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 700.38% 97% N/A 98% N/A
Average Annual (5 Year Horizon)  
Capital Gain 110.03% 93% A 95% A
Dividend Return 110.03% 93% A 95% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 225.91% 12% F 7% C-
Risk Adjusted Return 48.71% 93% A 79% B-
Market Capitalization 0.02B 97% N/A 91% A-

Key Financial Ratios

  Ratio vs. Industry/Classification (Biotechnology) Ratio vs. Market (NASDAQ Capital Market)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 21.71 7% 5%
Price / Cash Flow Ratio -94.30 100% 96%
Price/Free Cash Flow Ratio -71.64 99% 96%
Management Effectiveness  
Return on Equity -17.55% 89% 45%
Return on Invested Capital -40.84% 64% 25%
Return on Assets -12.78% 85% 31%
Debt to Equity Ratio N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector